The Southwest Oncology Group, first organized as a pediatric oncology group in 1956, has evolved into an adult multi-disease, multi-modality clinical research organization. This organization has grown to include 34 Full Member Institutions, 26 Community Clinical Oncology Program (CCOP) institutions, including 7 Minority-Based CCOPs, 23 Urologic Cancer Outreach Program (UCOP) members, 25 High Priority program members and a network of approximately 1,008 Cooperative Group Outreach Program (CGOP) investigators at 291 affiliate hospitals. In addition, 20 Group institutions also participate in the CTEP Minority Initiative Program, which serves to enhance minority accrual in cancer clinical trials. Approximately 3,542 oncologists, representing all research modalities, are members of the Group and actively participate in the registration of patients to oncology protocols. This Competitive Renewal Application is submitted to fund the Southwest Oncology Group to continue its unparalleled successes in accrual contributions in excess of 8,000 patients per year and timely completion of innovative, high quality cancer clinical trials. The scientific thrust of this Group is through the multidisciplinary disease-oriented committees, which collaborate in the design and development of the Group's therapeutic and ancillary trials. Significant components of this application include a major emphasis of this cooperative group to increase minority participation in clinical trials through the addition of seven Minority-based CCOPS, participation of 20 Group institutions in the CTEP Minority Initiative Program and the formation of a Minorities Subcommittee in the Cancer Control Research Committee. Accrual of women to Group clinical trials has also been highlighted as a significant priority of the Group; the formation of a Women's Task Force has been formed to specifically address women's clinical cancer research issues and serve as the liaison for the Group and NCI's Women's Health Initiative. The Southwest Oncology Group also continues to promote and strengthen its internationally-known expertise in cancer control and prevention research through the efforts of the Cancer Control Research Committee, particularly in the areas of quality of life and chemoprevention. The Southwest Oncology Group has also developed a series of new scientific initiatives to target tumor biology studies and clinical correlates. Tumor Biology Subcommittees of specific Disease Committees have been formed and have developed supplemental applications to this Renewal for funding of new projects. Proposals by these and other Group committees are submitted for the following programs: sarcoma biology, central myeloma immunophenotyping laboratory, solid tumor repository, solid tumor cytogenetics, thoracic surgical clinical trials, breast prognostic factors and breast flow cytometry. An Initiative on Women's Health application is also submitted to request funding support for the development and implementation of research initiatives to address women's issues in the Group with respect to cancer clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA032102-14
Application #
2088287
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1981-07-16
Project End
1997-12-31
Budget Start
1994-01-01
Budget End
1994-12-31
Support Year
14
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Ctrc Research Foundation
Department
Type
DUNS #
City
San Antonio
State
TX
Country
United States
Zip Code
78229
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Francis, Prudence A; Pagani, Olivia; Fleming, Gini F et al. (2018) Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 379:122-137
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Stock, W; Diouf, B; Crews, K R et al. (2017) An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clin Pharmacol Ther 101:391-395
Manasanch, Elisabet E; Orlowski, Robert Z (2017) Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol 14:417-433
Regan, M M; Walley, B A; Francis, P A et al. (2017) Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 28:2225-2232
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892

Showing the most recent 10 out of 742 publications